Navigation Links
MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
Date:1/26/2009

rally inhaled acute migraine medication in development which has a multi-targeted mechanism of action, utilizes the company's proprietary TEMPO(R) inhaler and is designed to optimize the key characteristics of dihydroergotamine, an active ingredient which has been used to effectively and safely treat migraines for over 60 years. MAP0004 has the potential to provide a faster onset of action than currently available migraine treatments, with sustained pain relief and pain freedom, in an easy-to-use, non-invasive, at-home therapy. In a Phase 2 clinical trial, patients reported pain relief in as fast as 10 minutes, with sustained relief to 24 and 48 hours. The safety data generated to date have shown MAP0004 to be well tolerated with no significant adverse events reported.

Migraine is a common, debilitating neurological disease affecting approximately 30 million people in the United States, according to the National Headache Foundation (NHF). Common symptoms include recurrent attacks of headaches, nausea, vomiting and sensitivity to light and sound. According to the NHF, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technolo
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Cumberland Pharmaceuticals Appoints Lee Product Director
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
8. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Texas, March 28, 2012   Luminex Corporation ... Dr. Amy Altman, vice president of Biodefense will ... Conference , taking place March 27-29, 2012 in Denver, Colorado. ... of Defense,s Joint Program Executive Office for ...
... SAN DIEGO, March 28, 2012 OncoSec Medical ... OncoSec Medical System (OMS) ElectroOncology therapies to treat solid ... to institutional investors of an aggregate of 31,000,000 shares ... a registered public offering.  Additionally, investors received Warrants to ...
... cloaking, a team of French researchers has proposed isolating or ... which the researchers describe in the Optical Society,s ( OSA ... into some of the same principles as optical cloaking and ... and, on an even larger scale, might someday prove useful ...
Cached Biology Technology:Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference 2Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference 3Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference 4OncoSec Closes $7.75 Million Public Offering 2OncoSec Closes $7.75 Million Public Offering 3Not your average heat shield 2
(Date:4/17/2014)... A Kansas State University engineer has developed a ... detects improvised explosive devices. The same technique could ... the Steven M. and Kay L. Theede chair ... nuclear engineering, and his research team have created ... or in car trunks. The distance detection method ...
(Date:4/17/2014)... Rajendra Singh Thursday as a "Champion of Change" ... deployment in the residential, commercial and industrial sectors. ... Electrical and Computer Engineering and director of Clemson,s ... hero leading the charge across the country to ... and driving policy changes at the local level ...
(Date:4/17/2014)... Ongoing deforestation and fragmentation of forests in the ... remnant forests, contributing to rapid and widespread forest ... of researchers., The findings show that forests in ... severe droughts coupled with forest fires lead to ... said Jennifer Balch, assistant professor of geography, Penn ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2White House honors Clemson professor as 'Champion of Change' for solar deployment 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3
... time to stop thinking of solar energy as a boutique ... generates about 1 percent of the electricity in the US. ... an associate professor of electrical engineering and materials science at ... to go mainstream. It,s a matter of economics. A ...
... WEST LAFAYETTE, Ind. - Wheat,s genetic resistance to Hessian flies ... U.S. Department of Agriculture scientists believe that other plants may ... Purdue and USDA research team developed a method to test ... simulates the effect of a transgenic plant without the lengthy ...
... team at Worcester Polytechnic Institute (WPI) has received a ... develop a smart phone application that will help people ... disease. The four-year project will be organized through WPI,s ... wound care specialists at the University of Massachusetts Medical ...
Cached Biology News:Affordable solar? 2Wheat can't stop Hessian flies, so scientists find reinforcements 2WPI receives $1.2 million to develop smart phone app for advanced diabetes and wound care 2WPI receives $1.2 million to develop smart phone app for advanced diabetes and wound care 3WPI receives $1.2 million to develop smart phone app for advanced diabetes and wound care 4
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Ubiquitin-like protein 4A (Ubiquitin-like protein GDX). [Source:Uniprot/SWISSPROT;Acc:P11441] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
...
Biology Products: